|
Dear All,
The highlight of this issue is important papers related to ILD in CTDs, in the ‘Practice Matters’ section of the newsletter. Long-term data related to commonly used drugs in clinical practice in this group of patients have been included. Cyclophosphamide, mycophenolate mofetil, azathioprine, and tacrolimus have been found to be useful in these reports, while rituximab results were inconclusive. Lung transplant survival in systemic sclerosis patients at 1year, 3years, and 5 years was 94%, 77%, and 70%, respectively, and similar to the other groups. This was single-center data from UCLA Medical Center, California published in the April issue of Annals of Thoracic Society (Miele CH et al., Ann Am Thorac Soc. 2016 Apr 14.) Which group of biologic agents has the maximum risk of ILD? This question was answered by Curtis JR and his team work that was published in Arthritis Res Ther. 2015 Nov 11; 17:319. In this paper, the authors identified 13,795 episodes of biologic exposure in 11,219 patients. The authors concluded that there were no significant differences in the risk of ILD and its related complications between RA patients receiving anti-TNFα agents and those receiving alternate mechanism of action (MOA: e.g. T-cell, B-cell, and interleukin-6 inhibitors) agents.
We welcome your suggestions to improve this IRA activity. Please post your suggestions/comments:
iraenewsletter@hotmail.com
Website: www.iraenewsletter.com
Regards,
Banwari Sharma
Editor, IRA e-Newsletter
|
|
